AndhraNews.net
Home » Business News » 2014 » November » November 3, 2014

VIVUS Announces Qsymia Presentations at Obesity Week 2014


November 3, 2014 - Mountain View, CA

MOUNTAIN VIEW, CA--(Marketwired - November 03, 2014) - VIVUS, Inc. (NASDAQ: VVUS), a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today announced the following presentations at Obesity Week 2014, Boston Convention and Exhibit Center.

Abstract Title: Effects of Phentermine and Topiramate Extended-Release (PHEN/TPM ER) Treatment on Weight Loss (WL) and Metabolic Syndrome (MetS) Parameters in Subjects with Body Mass Index (BMI) ≥35kg/m2
Authors: Nancy JV Bohannon, MD; Robert F. Kushner, MD; Sarah Odeh, BS;
Roman V. Dvorak, MD, PhD
Date/Time: Wednesday, November 5, 2014 from 5:30 to 7:00PM ET
Location: Boston Convention and Exhibition Center
Poster Session 2

Abstract Title: Effects of Phentermine and Topiramate Extended-Release (PHEN/TPM ER) on Weight Loss (WL), Risk of Type 2 Diabetes Mellitus (T2DM), and Concomitant Medication Costs in Older Obese/Overweight Subjects
Authors: Timothy Church, MD, PhD; Lucia Bonnemaison, PhD
Date/Time: Thursday, November 6, 2014 from 12:00 to 1:30 PM ET
Location: Boston Convention and Exhibition Center
Poster Session 3

Abstract Title: Effects of Phentermine and Topiramate Extended-Release (PHEN/TPM ER) on Weight Loss (WL) in Older Obese/Overweight Subjects Over 2 Years
Authors: Donna Ryan, MD; Sunil Karnawat, PhD; Sarah Odeh, BS
Date/Time: Thursday, November 6, 2014 from 12:00 to 1:30 PM ET
Location: Boston Convention and Exhibition Center
Poster Session 3

Abstract Title: Medication Cost-Offsets Associated with Phentermine/Topiramate Extended-Release (PHEN/TPM ER)-Induced Weight Loss (WL) in Subjects with Edmonton Obesity Staging System (EOSS) Stage 2
Authors: Arya M. Sharma, MD, PhD; Donna Ryan, MD; Wesley W. Day, PhD
Date/Time: Thursday, November 6, 2014 from 12:00 to 1:30 PM ET
Location: Boston Convention and Exhibition Center
Poster Session 3

Abstract Title: Prospective, Pharmacoepidemiologic Database Analysis of Qsymia® (Phentermine and Topiramate Extended-Release [PHEN/TPM ER]) Usage from a Representative US Sample of Patients
Authors: Craig A. Peterson, MS; Xanna Steelman, BA; Antoinette Stroh, BS;
Santosh T. Varghese, MD
Date/Time: Thursday, November 6, 2014 from 12:00 to 1:30 PM ET
Location: Boston Convention and Exhibition Center
Poster Session 3

About Qsymia

Qsymia® is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial Body Mass Index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 Diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for Weight Loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia® (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.

The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS

VIVUS is a biopharmaceutical company commercializing Qsymia® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ended December 31, 2013 as filed on February 28, 2014 and as amended by the Form 10-K/A filed on April 30, 2014, and periodic reports filed with the Securities and Exchange Commission.

VIVUS, Inc.
Dana B. Shinbaum
Corporate Development &
Investor Relations
shinbaum@vivus.com
650-934-5200

Investor Relations: The Trout Group
Brian Korb
Senior Vice President
bkorb@troutgroup.com
646-378-2923

MarketWire

Comment on this story

Share